performed targeted DNA sequencing on tumor tissue or pleural effusion samples and found that PARP1 mutation, MYC amplification, and a higher tumor mutational burden (TMB) were negative predictive biomarkers for PFS in EGFR T790M‐positive NSCLC receiving second‐line osimertinib treatment [11]. The gene discussed is PARP1; the disease is neoplasm.